Published in Infect Drug Resist on July 31, 2017
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Major facilitator superfamily. Microbiol Mol Biol Rev (1998) 9.77
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis (2005) 5.25
Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother (1998) 4.93
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis (2009) 4.59
ABC transporters: the power to change. Nat Rev Mol Cell Biol (2009) 4.48
The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis (1998) 4.33
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother (1996) 4.24
Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science (2006) 4.09
Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2001) 4.05
Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis (1995) 3.69
Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1992) 3.23
Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (1999) 3.19
Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol (2003) 3.12
Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother (1998) 3.09
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol (2010) 2.89
The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother (1999) 2.87
Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J (2002) 2.81
Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett (1997) 2.72
The direct cost and incidence of systemic fungal infections. Value Health (2002) 2.64
Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol (2005) 2.47
Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1997) 2.27
Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis (2009) 2.26
Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell (2007) 2.25
The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. J Bacteriol (1999) 2.11
Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol (2009) 2.02
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis (1997) 2.00
Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother (2004) 1.98
Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother (2003) 1.98
The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog (2007) 1.94
Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis (2012) 1.91
Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol (2008) 1.90
Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol Microbiol (2000) 1.77
Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog (2009) 1.76
Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob Agents Chemother (2005) 1.76
Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother (2002) 1.75
Formation of new chromosomes as a virulence mechanism in yeast Candida glabrata. Proc Natl Acad Sci U S A (2009) 1.69
A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. PLoS Biol (2014) 1.69
A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell (2008) 1.67
Molecular mechanisms of azole resistance in fungi. FEMS Microbiol Lett (1997) 1.66
Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol (2007) 1.65
Chromosome 1 trisomy compromises the virulence of Candida albicans. Mol Microbiol (2004) 1.61
Multidrug-resistant Candida auris: 'new kid on the block' in hospital-associated infections? J Hosp Infect (2016) 1.60
Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother (1997) 1.54
Sequential gene disruption in Candida albicans by FLP-mediated site-specific recombination. Mol Microbiol (1999) 1.54
Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother (1998) 1.52
Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis (2010) 1.49
Candida auris-associated candidemia, South Africa. Emerg Infect Dis (2014) 1.44
Chromosome instability in Candida albicans. FEMS Yeast Res (2007) 1.43
Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob Agents Chemother (2010) 1.39
An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob Agents Chemother (2009) 1.36
Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol (2003) 1.35
Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae. J Bacteriol (1999) 1.34
Yeast ATP-binding cassette transporters conferring multidrug resistance. Annu Rev Microbiol (2012) 1.33
Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One (2015) 1.30
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother (2000) 1.28
The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol Microbiol (2008) 1.26
Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother (2010) 1.26
Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother (2003) 1.25
Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents Chemother (2011) 1.24
Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses (1995) 1.23
Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother (2005) 1.21
Inactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicans. Antimicrob Agents Chemother (2005) 1.21
The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother (2000) 1.19
First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J Infect (2016) 1.19
Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob Agents Chemother (2010) 1.18
Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene (1999) 1.16
Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell (2012) 1.16
Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals. Biochem Soc Trans (1991) 1.15
Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog (2010) 1.14
Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob Agents Chemother (2009) 1.13
Evaluation of fluconazole resistance mechanisms in candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis (2004) 1.10
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis (2015) 1.09
Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother (2000) 1.09
Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Med Mycol (2001) 1.09
An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob Agents Chemother (2010) 1.09
Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species. mSphere (2016) 1.07
Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon. Eukaryot Cell (2010) 1.07
Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother (2012) 1.05
MFS transportome of the human pathogenic yeast Candida albicans. BMC Genomics (2008) 1.04
Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrob Agents Chemother (2013) 1.03
Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother (2008) 1.03
Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. J Med Vet Mycol (1997) 1.03
Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot Cell (2009) 1.02
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrob Agents Chemother (2008) 1.01
The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans. Mol Microbiol (2012) 1.01
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis (2016) 0.99
Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob Agents Chemother (2006) 0.98
Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob Agents Chemother (2012) 0.96
Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system. Antimicrob Agents Chemother (2014) 0.95
Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother (2014) 0.92
First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control (2016) 0.91
Evolutionary dynamics of Candida albicans during in vitro evolution. Eukaryot Cell (2011) 0.90
Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J Antimicrob Chemother (2010) 0.88
Upregulation of the ERG11 gene in Candida krusei by azoles. Daru (2010) 0.86
Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res (2013) 0.86
Analysis of a fungus-specific transcription factor family, the Candida albicans zinc cluster proteins, by artificial activation. Mol Microbiol (2013) 0.84
Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae. Antimicrob Agents Chemother (2015) 0.84
Predicting the emergence of resistance to antifungal drugs. FEMS Microbiol Lett (2001) 0.83
Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis. J Mass Spectrom (2002) 0.83
Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa. J Antimicrob Chemother (2016) 0.83
Detection of neonatal unit clusters of Candida parapsilosis fungaemia by microsatellite genotyping: Results from laboratory-based sentinel surveillance, South Africa, 2009-2010. Mycoses (2017) 0.75
Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA. J Antimicrob Chemother (2017) 0.75